PPARGC1B, PPARG coactivator 1 beta, 133522

N. diseases: 102; N. variants: 16
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 AlteredExpression disease BEFREE mRNA and protein expression of PGC-1β and FOXA2 in breast cancer tissues and cell lines were determined by qRT-PCR and Western Blotting, respectively. 31007610 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 AlteredExpression disease BEFREE mRNA and protein expression of PGC-1β and FOXA2 in breast cancer tissues and cell lines were determined by qRT-PCR and Western Blotting, respectively. 31007610 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 AlteredExpression disease BEFREE Using quantitative PCR and immunoblotting, we showed that breast cancer cells with HER2-amplification (SKBR-3) have greater expression of PGC-1β as compared to a non-tumorous breast cell (MCF-10A) and higher proliferation rate. 26602383 2016
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 GeneticVariation disease BEFREE To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro 1 2Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC). 27557380 2016
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 AlteredExpression disease BEFREE Using quantitative PCR and immunoblotting, we showed that breast cancer cells with HER2-amplification (SKBR-3) have greater expression of PGC-1β as compared to a non-tumorous breast cell (MCF-10A) and higher proliferation rate. 26602383 2016
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 GeneticVariation disease BEFREE To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro 1 2Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC). 27557380 2016
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 Biomarker disease BEFREE Apoptosis induced by PGC-1β in breast cancer cells is mediated by the mTOR pathway. 23877360 2013
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 GeneticVariation disease BEFREE PPARγ and PPARGC1B polymorphisms modulate the association between phthalate exposure and BC risk. 23866026 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 Biomarker disease BEFREE Apoptosis induced by PGC-1β in breast cancer cells is mediated by the mTOR pathway. 23877360 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 GeneticVariation disease BEFREE PPARγ and PPARGC1B polymorphisms modulate the association between phthalate exposure and BC risk. 23866026 2013
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 Biomarker disease BEFREE PGC-1β knockdown in breast cancer cells impaired ERRα signaling and reduced cell proliferation, implicating a functional role for PGC-1β/ERRα in the pathogenesis of breast cancers. 22014575 2011
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 Biomarker disease BEFREE PGC-1β knockdown in breast cancer cells impaired ERRα signaling and reduced cell proliferation, implicating a functional role for PGC-1β/ERRα in the pathogenesis of breast cancers. 22014575 2011
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 Biomarker disease CTD_human Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression. 20961995 2010
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 Biomarker disease BEFREE Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression. 20961995 2010
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 Biomarker disease BEFREE Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression. 20961995 2010
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 Biomarker disease CTD_human Taken together, our results suggest that ERRα and PGC-1β are key players in the etiology of malignant breast cancer by coordinating the transcriptional regulation of genes located in the 17q12 region, a process that also involves interference with the repressive function of ERα on ERBB2 expression. 20961995 2010
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 GeneticVariation disease BEFREE The genotype-combination analysis of the associated PPARGC1A Thr612Met variant and the associated PPARGC1B Ala203Pro variant suggests an allele dose-dependent breast cancer risk (P(trend) = 0.0004). 16704985 2006
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 GeneticVariation disease BEFREE The genotype-combination analysis of the associated PPARGC1A Thr612Met variant and the associated PPARGC1B Ala203Pro variant suggests an allele dose-dependent breast cancer risk (P(trend) = 0.0004). 16704985 2006
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.390 AlteredExpression disease BEFREE We conclude that there is aberrant expression of PPARgamma and its co-activator, PGC-1, in human breast cancer and low levels of these molecules in cancer tissues are associated with poor clinical outcomes. 12866036 2003
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.390 AlteredExpression disease BEFREE We conclude that there is aberrant expression of PPARgamma and its co-activator, PGC-1, in human breast cancer and low levels of these molecules in cancer tissues are associated with poor clinical outcomes. 12866036 2003
CUI: C0028754
Disease: Obesity
Obesity
0.370 Biomarker disease CTD_human Mitochondrial-related gene associated to obesity can be modulated by in utero hyperglycemic environment. 30738174 2019
CUI: C0028754
Disease: Obesity
Obesity
0.370 Biomarker disease BEFREE The aim of the present study was to determine the possible association of five single-nucleotide polymorphisms (SNPs) located in the IGF2, LEPR, POMC, PPARG, and PPARGC1 genes with obesity or obesity-related risk phenotypes. 25923461 2015
CUI: C0028754
Disease: Obesity
Obesity
0.370 Biomarker disease BEFREE In this review, we outline the function of PGC-1 coactivators in physiological and pathological conditions as well as the complex interplay of metabolic dysregulation and inflammation in obesity with special focus on skeletal muscle. 24258516 2014
CUI: C0028754
Disease: Obesity
Obesity
0.370 Biomarker disease BEFREE Peroxisome proliferator-activated receptor gamma co-activator 1beta (PPARGC1B) may play an important role in obesity and Type 2 diabetes mellitus (T2DM). 16759305 2006
CUI: C0028754
Disease: Obesity
Obesity
0.370 GeneticVariation disease BEFREE We studied variation in the coding region of human PPARGC1B in Danish whites and related these variations to the prevalence of obesity and type 2 diabetes in population based samples. 15863669 2005